PDL BioPharma (NASDAQ: PDLI) reported Q3 EPS of $0.61, $0.05 better than the analyst estimate of $0.56. Revenue for the quarter came in at $164.6 million versus the consensus estimate of $165.1 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.